Hemolytic Anemia
📧 Sign up to get email alerts when something new happens for Hemolytic Anemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-13EMA Authorised: Pyrukynd (mitapivat sulfate) — Agios Netherlands B.V.
Pyrukynd (mitapivat sulfate) has been authorised in the EU for genetic diseases inborn and hemolytic anemia, with orphan medicine designatio…
-
EMA approval · 2026-07-09EMA Authorised: Pyrukynd (mitapivat sulfate) — Agios Netherlands B.V.
Pyrukynd (mitapivat sulfate) has been authorised in the EU for genetic diseases inborn and hemolytic anemia, orphan medicine designation.
-
EMA approval · 2026-04-21EMA Authorised: Pyrukynd (mitapivat sulfate) — Agios Netherlands B.V.
The European Medicines Agency authorised Pyrukynd (mitapivat) for the treatment of pyruvate kinase deficiency—a genetic cause of hemolytic a…